Popular on EntSun
- UK Financial Ltd Announces A Special Board Meeting Today At 4PM: Orders MCAT Lock on CATEX, Adopts ERC-3643 Standard, & Cancels $0.20 MCOIN for $1 - 263
- MROVI Trailer Parts Launches Its Own Tire Brand: Introducing MROVI Tires and the New Didgori Trail Tread - 169
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels - 148
- ProfileSpider Launches Powerful One-Click Profile Scraper for Recruiters and Growth Teams - 141
- Touch Massage London Unveils Premium Local Massage Services to Transform Wellbeing Across the Capital - 137
- Verb™ Presents Features Vanguard Personalized Indexing: Utilizing Advanced Tax-Loss Harvesting Technology - 124
- Viola's Babygirl's, LLC Proudly Announces Teri Tobin's Soulful New Christmas EP "Home For The Holidays" - 117
- Finally, Archive Videos at Lower Price With KeepStreams' Black Friday Deal! - 116
- "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society - 114
- Uk Financial Ltd Featured In New York Business Now — 2019 Gold-Backed Bitcoin Prediction Now Becomes SEC Security Token Filing - 114
Similar on EntSun
- Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026
- Renowned Alternative Medicine Specialist Dr. Sebi and His African Bio Mineral Balance Therapy Are the Focus of New Book
- Psychiatric Drug Damage Ignored for Decades; CCHR Demands Federal Action
- Why Millions Are Losing Sexual Sensation, And Why It's Not Age, Hormones, or Desire
- Pinealage: the app that turns strangers into meditation companions — in crowdfunding phase
- "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society
- Women's Everyday Safety Is Changing - The Blue Luna Shows How
- Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
- NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
Sedia Biosciences Board Announces Changes to Executive Leadership
EntSun News/10863488
The Board of Directors of Sedia Biosciences Corporation today announced a series of changes to the Company's executive management team.
BEAVERTON, Ore. - EntSun -- Roger I. Gale, previously Chief Executive Officer and Chairman of the Board of Directors, was appointed Executive Chairman of Sedia. Mr. Gale is a co-founder of Sedia. Dr. Lynn Stevenson, Member of the Board of Directors said "Mr. Gale has been instrumental in the Company's evolution and growth. His international experience as an executive for both large and small corporations has brought a unique perspective and played a critical role in its success. Mr. Gale will continue to drive for growth with an ever-present entrepreneurial mindset in his new role as Executive Chairman."
Ronald W. Mink, Ph.D., was appointed Chief Executive Officer. Dr. Mink was previously President and Chief Science Officer. He was reappointed President and will also serve as interim Chief Science Officer. Dr. Mink is a co-founder of Sedia. Roger Gale said "In his previous roles as President and Chief Science Officer, Dr. Mink made outstanding contributions to the growth and scale-up of Sedia's premier HIV products, while simultaneously leading research and development efforts toward novel product lines. His leadership skills, depth of scientific knowledge and passion for innovation will serve the Company well in his new role as Chief Executive Officer."
More on EntSun News
Nancy Lime, previously Senior Vice President, Operations, was appointed Chief Operating Officer. Dr. Mink said "In her previous role as Senior Vice President, Operations, Ms. Lime has had a major impact on the performance of the Company. Over the past two years she has helped drive growth in production capacity, sales revenue and profitability and made a significant contribution to improvements in our quality systems. In 2020, she also led the design, build-out and relocation of the Company to our new assay development and manufacturing facility. Ms. Lime's experience, leadership and drive will serve the Company well in her new role as Chief Operating Officer."
Clay Roscoe, MD, MSc, previously Medical Advisor to the Company, was appointed Chief Medical Officer. Dr. Mink said "Dr. Roscoe brings to the Company years of clinical practice in HIV medicine and experience with the U.S. Centers for Disease Control (CDC) in Namibia, Southern Africa. Dr. Roscoe's field experience working first-hand with patients and leading national diagnostic assay programs for both HIV and TB will provide invaluable knowledge and insight for new product development and market analysis. We are pleased to welcome Dr. Roscoe to the team."
Jason Boone, Ph.D., was appointed President of Floragenex, a wholly owned subsidiary of Sedia. Dr. Boone will continue to serve as Sedia's Vice President of Sales and Marketing. Dr. Mink said "Dr. Boone began with Floragenex in 2009 and has continued to implement processes to facilitate growth for the Company. With a keen business acumen, scientific expertise, and enthusiasm in growing start-up companies, we are pleased to have Dr. Boone driving our Sales and Marketing program and serving in the role of President of Floragenex."
More on EntSun News
About Sedia Biosciences Corporation
Sedia Biosciences is a privately held medical device and diagnostics company founded in 2009 and is based in Beaverton, Oregon, USA. Our goal is to become a leader in three areas intended to advance global access to care: (1) state-of-the-art rapid point-of-care diagnostic assays, (2) novel epidemiological disease surveillance assays and other Public Health tools and (3) innovative clinical specimen collection devices to improve and facilitate remote collection of specimens for follow-up testing. Sedia brings together a dedicated team of scientists and businesspeople that share a common mission: to improve access to medical care around the world by providing innovative diagnostic, epidemiological and clinical products.
Follow us on Facebook, LinkedIn, Twitter or at our website: www.sediabio.com
Ronald W. Mink, Ph.D., was appointed Chief Executive Officer. Dr. Mink was previously President and Chief Science Officer. He was reappointed President and will also serve as interim Chief Science Officer. Dr. Mink is a co-founder of Sedia. Roger Gale said "In his previous roles as President and Chief Science Officer, Dr. Mink made outstanding contributions to the growth and scale-up of Sedia's premier HIV products, while simultaneously leading research and development efforts toward novel product lines. His leadership skills, depth of scientific knowledge and passion for innovation will serve the Company well in his new role as Chief Executive Officer."
More on EntSun News
- Leimert Park Announces Weeklong Kwanzaa Festival & Kwanzaa Parade Celebrating Black History, Culture, and Community
- FullCircle Festival-An Exploration of New Orleans' Black Heritage
- Renowned Alternative Medicine Specialist Dr. Sebi and His African Bio Mineral Balance Therapy Are the Focus of New Book
- 'Beyond the Ashes: An Adaptive Trail Story' Documentary Celebrates Adaptive Mountain Bikers
- Psychiatric Drug Damage Ignored for Decades; CCHR Demands Federal Action
Nancy Lime, previously Senior Vice President, Operations, was appointed Chief Operating Officer. Dr. Mink said "In her previous role as Senior Vice President, Operations, Ms. Lime has had a major impact on the performance of the Company. Over the past two years she has helped drive growth in production capacity, sales revenue and profitability and made a significant contribution to improvements in our quality systems. In 2020, she also led the design, build-out and relocation of the Company to our new assay development and manufacturing facility. Ms. Lime's experience, leadership and drive will serve the Company well in her new role as Chief Operating Officer."
Clay Roscoe, MD, MSc, previously Medical Advisor to the Company, was appointed Chief Medical Officer. Dr. Mink said "Dr. Roscoe brings to the Company years of clinical practice in HIV medicine and experience with the U.S. Centers for Disease Control (CDC) in Namibia, Southern Africa. Dr. Roscoe's field experience working first-hand with patients and leading national diagnostic assay programs for both HIV and TB will provide invaluable knowledge and insight for new product development and market analysis. We are pleased to welcome Dr. Roscoe to the team."
Jason Boone, Ph.D., was appointed President of Floragenex, a wholly owned subsidiary of Sedia. Dr. Boone will continue to serve as Sedia's Vice President of Sales and Marketing. Dr. Mink said "Dr. Boone began with Floragenex in 2009 and has continued to implement processes to facilitate growth for the Company. With a keen business acumen, scientific expertise, and enthusiasm in growing start-up companies, we are pleased to have Dr. Boone driving our Sales and Marketing program and serving in the role of President of Floragenex."
More on EntSun News
- Why Millions Are Losing Sexual Sensation, And Why It's Not Age, Hormones, or Desire
- Justin Jeansonne An Emerging Country Singer-Songwriter Music Fans Have Been Waiting For…a True Maverick
- Russellville Huntington Learning Center Expands Access to Literacy Support; Approved Provider Under Arkansas Department of Education
- UK Financial Ltd Launches U.S. Operations Following Delaware Approval
- Lloyd, Ricci, Feldman, Phelps Twins Among Major Last-Month Additions to FAN EXPO New Orleans
About Sedia Biosciences Corporation
Sedia Biosciences is a privately held medical device and diagnostics company founded in 2009 and is based in Beaverton, Oregon, USA. Our goal is to become a leader in three areas intended to advance global access to care: (1) state-of-the-art rapid point-of-care diagnostic assays, (2) novel epidemiological disease surveillance assays and other Public Health tools and (3) innovative clinical specimen collection devices to improve and facilitate remote collection of specimens for follow-up testing. Sedia brings together a dedicated team of scientists and businesspeople that share a common mission: to improve access to medical care around the world by providing innovative diagnostic, epidemiological and clinical products.
Follow us on Facebook, LinkedIn, Twitter or at our website: www.sediabio.com
Source: Sedia Biosciences Corporation
Filed Under: Health
0 Comments
Latest on EntSun News
- Bay Street Yard announces New Year's Eve Celebration
- 5-Star Duncan Injury Group Expands Personal Injury Representation to Arizona
- The End of "Influencer" Gambling: Bonusetu Analyzes Finland's Strict New Casino Marketing Laws
- AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
- TRIO Heating, Air & Plumbing Now Ranks #1 in San Jose
- Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
- Power Couple Launches "Happy Habits Events" After Best of Philly Win, Pandemic Loss, and Setbacks
- Clean Comedy Kings Debuts At Black Oak Casino Saturday January 3rd
- Golden Paper Identifies Global Growth in Packaging Papers and Upgrades Its High-End Production Capacity
- Live Performance at the Bal Theater by Angel Sessions
- Detroit-Born Puzzle Game Launches Nationwide XIXMAS Challenge With Gaming PC Giveaway
- Champagne, Caviar Bumps & Pole Performances — Welcome the New Year Early with HandPicked Social Club
- A New Soul Album: Heart Of Kwanzaa, 7-Day Celebration
- Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
- NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
- Costa Oil - 10 Minute Oil Change Surpasses 70 Locations with Construction of San Antonio, TX Stores — Eyes Growth Via Acquisition or Being Acquired
- LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
- Amazing Hotels Inc Announces A Luxury Hotel & Entertainment Complex On 500+/- Lakefront Acres
- Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
